Navigation Links
New Migraine Drug Shows Promise
Date:11/24/2008

Telcagepant works differently than standard triptans, researchers say

MONDAY, Nov. 24 (HealthDay News) -- A drug called telcagepant proved safe and effective in treating migraines and caused fewer side effects than the widely-used migraine drug zolmitriptan (Zomig), according to a study conducted by drug maker Merck & Co.

Zolmitriptan and other triptans are effective but can cause a number of side effects, including dizziness, tingling and numbness of the skin, chest discomfort, and throat tightness. In addition, triptans cause blood vessel narrowing and aren't recommended for patients with cardiovascular disease, high blood pressure and certain migraine subtypes, according to a news release about the study.

Telcagepant is from a different class, called calcitonin gene-related peptide (CGRP) antagonists. It's believed that brain concentrations of CGRP are elevated during a migraine. CGRP antagonists don't seem to have blood vessel narrowing properties and, therefore, may not carry the same cardiovascular-related risks as triptans.

This phase III study included 1,380 patients at 81 sites in Europe and the United States. The patients, who suffered from moderate or severe migraines, received either 150 milligrams or 300 milligrams of telcagepant, 5 milligrams zolmitriptan, or a placebo.

The 300-milligram dose of telcagepant was more effective than placebo for freedom from pain (27 percent of patients vs. 10 percent), pain relief (55 percent vs. 28 percent), absences of noise sensitivity (58 percent vs. 37 percent) and light sensitivity (51 percent vs. 29 percent), and nausea (65 percent vs. 55 percent), according to the study.

Telcagepant 300 milligram and zolmitriptan 5 milligram were similarly effective in treating migraines, and both were more effective than telcagepant 150 milligram. Negative side effects were reported by 31 percent of patients taking telcagepant 150 milligram, 32 percent taking placebo, 37 percent taking telcagepant 300 milligram, and 51 percent taking 5 milligram zolmitriptan.

"One potential benefit of the new CGRP receptor antagonist class of acute migraine treatments is the absence of vasoconstriction, a liability of the triptans, which may allow for the safe administration of telcagepant in patients with migraine with cardiovascular disease," the study authors wrote. "However, such patients were excluded from the present study because of the contraindication for zolmitriptan, and further studies are necessary to determine the safety of telcagepant in patients with cardiovascular disease. Additional studies are also necessary to assess the long-term efficacy and safety profile of telcagepant in patients treating more than one migraine attack."

The study was published online Nov. 25 and in an upcoming print issue of The Lancet. Preliminary results from the trial were presented in June at the American Headache Society's annual meeting, in Boston.

"This result marks a new era in migraine therapy. However, the remaining issue is to understand the site of action of the CGRP-receptor antagonists," Dr. Lars Edvinsson, of Lund University in Sweden, wrote in an editorial comment accompanying The Lancet study.

More information

The American Academy of Neurology has more about migraine treatments.



-- Robert Preidt



SOURCE: The Lancet, news release, Nov. 25, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Neuromuscular Dentistry Ends Womans Migraines
2. Migraine Tied to Thickening in Brain Area
3. Business Coalition Honors BlueChoice HealthPlan for Migraine Program
4. The HealthCentral Network Wins eHealthcare Awards for Breast Cancer and Migraine Web Sites
5. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
6. Comatose locusts may help relieve migraines
7. Epilepsy Drug Doesnt Prevent Migraines
8. MyMigraineConnection.com and Migraine Expert Teri Robert Announce Seventh Annual Migraine and Headache Poetry Contest
9. Migraines Frequency Influences Heart Attack, Stroke Risk
10. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
11. Skin Pain, Sensitivity Rises With Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Migraine Drug Shows Promise
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
Breaking Medicine Technology: